- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00683904
Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
February 9, 2016 updated by: R-Pharm
A Phase I Study of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer as First-line Treatment
The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥20 years
- Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)
- Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent
- No prior chemotherapy-containing regimens for the treatment of NSCLC
- Eastern Cooperative Oncology Group performance status of 0-1
- Life expectancy of at least 12 weeks
- Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1
- Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy)
Exclusion Criteria:
- Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug
- Women pregnant or breast feeding
- Women with a positive pregnancy test result on enrollment or prior to study drug administration
- Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP
- Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases
- Prior radiation must not have included ≥30% of major bone-marrow-containing areas (pelvis, lumbar spine)
- Common Terminology Criteria (CTC) Grade 2 or greater neuropathy
- Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements
- Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible)
- Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy.
- Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months
- Known history of infection with human immunodeficiency virus
- Inadequate bone marrow function
- Inadequate hepatic function
- Inadequate renal function
- Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL
- Known severe hypersensitivity reaction to agents containing carboplatin and other platinum
- Prior treatment with an epothilone and/or with platinum
- History of high-dose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years
- On treatment with strong Cytochrome P450 3A4 inhibitor
- Current imprisonment
- Compulsorily detention for treatment of psychiatric or physical illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
|
On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes.
Repeated once every 3 weeks, for a maximum of 6 cycles.
Other Names:
|
Active Comparator: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
|
After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened.
On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes.
Repeated once every 3 weeks, for a maximum of 6 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose-limiting Toxicity (DLT)
Time Frame: Days 1 through 21 (Cycle 1)
|
DLT is defined as any of the following: Common Terminology Criteria (CTC), Version 3, Grade(Gr) 4 neutropenia (absolute neutrophil count <500 cells/mm^3) for at least 5 days or febrile neutropenia; Gr 4 thrombocytopenia (<25,000 cells/mm^3 or bleeding needing platelet transfusion); Gr 3 or 4 nausea, vomiting, or diarrhea, despite medical intervention; any other drug-related Gr 3 or 4 nonhematologic toxicity, except Gr 3 injection site reaction, fatigue/asthenia, transient arthralgia/myalgia, or transient electrolytes abnormal.
Gr 1=Mild; Gr 2=Moderate; Gr 3=Severe; Gr 4=Life-threatening.
|
Days 1 through 21 (Cycle 1)
|
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of Carboplatin in Combination With Ixabepilone, 32 mg/m^2
Time Frame: Days 1 through 21 (Cycle 1)
|
The MTD was defined as the highest dose evaluated for which less than one sixth of patients experience a DLT in Cycle 1.
The recommended phase 2 dose is the MTD defined in Cycle 1, with consideration given to chronic cumulative toxicity occurring at later cycles.
|
Days 1 through 21 (Cycle 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Death as Outcome, Treatment-related Serious Adverse Events (SAEs), SAEs, Adverse Events (AEs), and Treatment-related AEs Leading to Discontinuation
Time Frame: Days 1 through 21 (Cycle 1)
|
An SAE is any untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongs existing hospitalization.
An AE is any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment.
Treatment-related comprises certainly, probably, and possibly related and of unknown relationship to study drug.
|
Days 1 through 21 (Cycle 1)
|
Number of Participants With Grade 3 or Greater Treatment-related AEs
Time Frame: Days 1 through 21 (Cycle 1)
|
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with treatment.
AEs graded according to CTC, Version 3.0.
Gr 1=Mild; Gr 2=Moderate; Gr 3=Severe; Gr 4=Life-threatening.
Treatment-related comprises certainly, probably, and possibly related and of unknown relationship to study drug.
|
Days 1 through 21 (Cycle 1)
|
Number of Participants With Abnormalities in Hematology Laboratory Values by Worst CTC Grade
Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days)
|
LLN=lower level of normal; ULN=upper level of normal. Hemoglobin (g/dL; LLN=11.3; ULN=14.9); leukocytes (*10^3 c/uL; LLN=4.1; ULN=6.1); lymphocytes (*10^3 c/uL); neutrophils (absolute), neutrophils + bands (*10^3 c/uL); platelet count (*10^9 c/L; LLN=131; ULN=365) Appendix 7.1.2 |
At screening and Days 8 and 15 of Cycle 1 (21 days)
|
Number of Participants With Abnormalities in Serum Chemistry Laboratory Values by Worst CTC Grade
Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days)
|
ULN=upper limit of normal; LLN=lower limit of normal.
Alkaline phosphatase=ALP(LLN=115; ULN=359) (U/L); alanine aminotransferase=ALT (LLN=8; ULN=42)(U/L); aspartate aminotransferase=AST (LLN=13; ULN=33) (U/L); albumin (LLN=3.7;
ULN=5.2)(g/dL);
bilirubin (LLN=0.3;
ULN=1.2)(mg/dL);
calcium (LLN=8.7;
ULN=10.3)(mg/dL);
creatinine (LLN=0.6;
ULN=1.1)(mg/dL);
potassium (LLN=3.6;
ULN=4.9)
(mEq/L); sodium (LLN=138; ULN=146) (mEq/L)
|
At screening and Days 8 and 15 of Cycle 1 (21 days)
|
Number of Participants With Abnormalities in Urine Testing Results by Worst CTC Grade
Time Frame: At screening and Days 8 and 15 of Cycle 1 (21 days)
|
Toxicities graded according to CTC, Version 3. Protein Gr 1: <1.0 g/24 hrs (1+); Gr 2: 1.0 to 3.4 g/24 hrs (2+ to 3+ ); Gr 3: >=3.5 g/24 hrs (4+); Gr 4: Nephrotic syndrome.
Note: + = qualitative measure of urine chemistry.
|
At screening and Days 8 and 15 of Cycle 1 (21 days)
|
Number of Participants With Abnormalities in Blood Pressure and Heart Rate
Time Frame: At screening and Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22)
|
Blood pressure and heart rate obtained before ixabepilone infusion, every 1 hour during and at the end of ixabepilone infusion, and at the end of carboplatin infusion in Cycle 1.
For subsequent cycles, vital signs obtained before ixabepilone infusion, at the end of ixabepilone infusion, and at the end of carboplatin infusion.
Any new or worsening clinically significant changes since last entry were recorded as appropriate AE or SAE.
|
At screening and Day 1 of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22)
|
Number of Participants With Abnormalities in Weight and Eastern Cooperative Oncology Group (ECOG) Performance Status
Time Frame: At screening of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22)
|
Participants weighed same day as serum chemistry tests.
Body surface area recalculated only if body weight changes >10%.
ECOG criteria used to assess disease progression and affects on daily living abilities and to determine appropriate treatment and prognosis.
Grade 1=Restricted physical activity but ambulatory and capable of light work; Grade 2=Ambulatory, capable of self care, but unable to carry out any work activities; Grade 3=Capable of limited self care, confined to bed or chair 50% or more of waking hours; Grade 4=Completely disabled, totally confined to bed or chair.
|
At screening of Cycle 1 (21 days) and Day 1 of Cycle 2 (Study day 22)
|
Number of Participants at Each Response Evaluation Criteria in Solid Tumors (RECIST) Assessment
Time Frame: Days 1 through 21 (Cycle 1)
|
Tumor response was assessed using the RECIST assessment: Complete response (CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial response (PR)=At least 30% reduction in the sum of the longest diameters of all target lesions; Progressive disease (PD)=At least 20% increase in the sum of the longest diameters of all target lesions; Stable disease (SD)=Neither PR nor PD criteria were met.
|
Days 1 through 21 (Cycle 1)
|
Maximum Observed Plasma Concentration of Ixabepilone
Time Frame: Days 1 to 8 of Cycle 1 (21 days)
|
Days 1 to 8 of Cycle 1 (21 days)
|
|
Time of Maximum Observed Plasma Concentration of Ixabepilone
Time Frame: Days 1 to 8 of Cycle 1 (21 days)
|
Days 1 to 8 of Cycle 1 (21 days)
|
|
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time of Ixabepilone
Time Frame: Days 1 to 8 of Cycle 1 (21 days)
|
Days 1 to 8 of Cycle 1 (21 days)
|
|
Volume of Distribution at Steady State of Ixabepilone
Time Frame: Days 1 to 8 of Cycle 1 (21 days)
|
Days 1 to 8 of Cycle 1 (21 days)
|
|
Total Body Clearance of Ixabepilone
Time Frame: Days 1 to 8 of Cycle 1 (21 days)
|
Days 1 to 8 of Cycle 1 (21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
May 22, 2008
First Submitted That Met QC Criteria
May 23, 2008
First Posted (Estimate)
May 26, 2008
Study Record Updates
Last Update Posted (Estimate)
March 10, 2016
Last Update Submitted That Met QC Criteria
February 9, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Carboplatin
- Epothilones
Other Study ID Numbers
- CA163-160
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer (NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
Clinical Trials on Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
-
R-PharmGlaxoSmithKlineTerminatedLocally Advanced or Metastatic Breast CancerUnited States, Italy, Australia
-
R-PharmTerminated
-
Merck Sharp & Dohme LLCCompletedSmall Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
-
R-PharmCompletedAdvanced/Metastatic Non-Small Cell Lung CancerGermany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
-
AmtixBio Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
Boehringer IngelheimTerminated
-
R-PharmCompletedMetastatic Breast CancerItaly, United Kingdom, United States, France, Spain
-
Boehringer IngelheimCompletedOvarian Neoplasms | Peritoneal NeoplasmsSpain
-
Merck Sharp & Dohme LLCCompletedNon-small Cell Lung CancerUnited States, Australia, France, Germany, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, United Kingdom
-
Hoffmann-La RocheCompletedColorectal CancerFrance, Israel, Italy, Spain, Sweden, Hong Kong, Australia, Canada, Switzerland, United States, Ireland, Denmark, Germany, Taiwan, Russian Federation, China, New Zealand, Austria, United Kingdom, Hungary, Thailand, South Africa, Mexico and more